MedTrait® Terms of Service
MedTrait is a product of PTC Laboratories, Inc. who is the sole owner of information collected on this site (medtrait.net) as well as ptclabs.com and genetrait.com.
We respect and protect your privacy. Our sites are SSL encrypted and is a safe and secure environment for anyone to visit and shop. We do not sell or share your information with any third parties and we are committed to protecting your rights as a consumer.
PTC Laboratories, Inc. will not sell, share, or rent this information to any outside parties, except for the sharing of addresses for shipping purposes to shipping vendors. We collect information from our customers to process orders and better serve you with pertinent information, such as order confirmations and order status updates. Information collected includes your name, shipping address, billing address, telephone numbers, e-mail address, and payment information such as your credit card number. We also require you to submit a username and password of your choice for your future access to your account information. To safeguard that your user name and password remain confidential, DO NOT share this information with anyone. If you elect to receive our newsletter or special promotions, your contact information will be used for the delivery of these items.
For more information, please
MedTrait® Original Laboratory-Issued Clinical Report
This genetic test and the reporting of clinical implications associated with specific genetic findings are intended to provide supplemental information to the healthcare provider in identifying the medication therapy best suited to each individual patient. This report does not constitute medical advice. The genetic test and reported clinical implications are intended to complement, not replace, clinical observations and other information used by the healthcare provider in determining the best medication treatment plan for the patient. The patient’s healthcare provider is responsible for providing medical advice and for making clinical decisions about medication management and treatment for the patient. As medical advice must be tailored to the specific circumstances of each patient, the treating healthcare provider has ultimate responsibility, and PTC Laboratories, Inc. and the performing laboratory disclaim any responsibility, for treatment decisions made with regard to the patient including any treatment decisions that take into account the patient’s genotype or other information provided in this report.
Information such as drug interaction dynamics, the impact of lifestyle factors, and duplicate therapy are derived from the Wolters Kluwer Medi-Span drug databases. Wolters Kluwer is solely responsible for the accuracy and completeness of their data. This data will change over time as new medications enter the market and current drug information is updated. While we believe that this report is based on comprehensive current scientific information, it is possible that not all relevant published scientific information has been included in this report and PTC Laboratories, Inc. and the performing laboratory disclaim responsibility for any omissions.
The individual alerts that are taken into consideration in the overall alert score include drug interactions for adverse drug reactions (0-5) and reduced efficacy (0-5), inherent drug risk of the target medication (0-5), and genetic interactions for adverse drug reactions (0-5) and non-efficacy (0-5). Individual alerts are rated on a scale of 0-5, where 0 represents no identified ADRs or efficacy issues and 5 equals some risk of serious injury or death. There is a maximum combined alert score of 25. The inherent drug risk of the target medication alone is established based on a number of factors including the frequency of monitoring necessary for the use of each medication. While use of required monitoring frequency is one indication of risk, it can sometimes cause the inherent risk to be somewhat overstated or understated. Lifestyle factors and duplicate therapy risk are not considered in calculating the overall drug risk, but information currently available about each may be provided in the report.
Potential alternative medications may be listed for medications provided that the total alert score for the alternative medication is less than the current medication. If the information provided to the performing laboratory does not indicate the medical condition that the current medication has been prescribed to address, alternative medications are identified in the same medication class for one of the most common uses of the medication, as denoted in the alternatives section. In some cases it will not be possible to identify a lower adverse drug reaction or non-efficacy medication in the same medication class.
These interpretations, including genetic risk factors and the clinical implications associated with specific genetic findings, are based upon data available in the scientific literature and prescribing information for the relevant drugs. Scientifically supported information about genetics and medications is updated over time. This report provides information based on the data available at the time of reporting, but may change in the future due to new discoveries and research. Apart from the medications and genetic factors considered in this laboratory report, the coadministration of other drugs that inhibit or induce the CYP enzymes, and other genetic and nongenetic factors, may alter the efficacy or toxicity of medications mentioned in this report.
Inclusion of any medication trade name in this report is not an indication of endorsement for a specific manufacturer or formulation of a medication. Commonly used trade names of medications may be provided in this report for reference. The provided names of medications may not represent all possible manufacturers or trade names of the denoted medication. Genetic reference citations and definitions of each risk scale are available upon request and within the MedTrait interactive web app.
MedTrait® User-Updated, Modified Report
Changes from the Original Laboratory-Issued Clinical Report
A user-updated MedTrait report is generated by the MedTrait interactive app at medtrait.app and is not a substitute for the original laboratory-issued report. This version of a MedTrait report can be identified by its “User-Updated” cover sheet outlining changes made to the patient’s medication list with the interactive app before exporting.
The original, laboratory-issued MedTrait report can always be obtained at medtrait.app after logging in with the patient’s data and clicking Report History > Original Report.
MedTrait® Interactive Web App
End-User License Agreement (“Agreement”)
Last updated: February 6, 2019
Please read this End-User License Agreement ("Agreement") carefully before using the MedTrait® interactive web app available at medtrait.app ("Application").
By using the Application, you are agreeing to be bound by the terms and conditions of this Agreement.
If you do not agree to the terms of this Agreement, do not use the Application.
PTC Laboratories, Inc. (“Company”) grants you a revocable, non-exclusive, non-transferable, limited license to use the Application solely for your personal, non-commercial purposes strictly in accordance with the terms of this Agreement.
You agree not to, and you will not permit others to:
a) license, sell, rent, lease, assign, distribute, transmit, host, outsource, disclose or otherwise commercially exploit the Application or make the Application available to any third party; b) decompile, reverse engineer, disassemble, attempt to derive the source code of, or decrypt the Application; c) make any modification, adaptation, improvement, enhancement, translation or derivative work from the Application; d) violate any applicable laws, rules or regulations in connection with Your access or use of the Application; e) remove, alter or obscure any proprietary notice (including any notice of copyright or trademark) of Company or its affiliates, partners, suppliers or the lincencors of the Application; f) use the Application for any revenue generating endeavor, commercial enterprise, or other purpose for which it is not designed or intended; g) use the Application for creating a product, service or software that is, directly or indirectly, competitive with or in any way a substitute for any services, product or software offered by Company; h) use the Application to send automated queries to any website or to send any unsolicited commercial e-mail; or i) use any proprietary information or interfaces of Company or other intellectual property of Company in the design, development, manufacture, licensing or distribution of any applications, accessories or devices for use with the Application.
You and Company acknowledge and agree that, in the event of a third party claim that the Application or Your possession or use of the Application infringes any third party’s intellectual property rights, You (and not Company) will be responsible for the investigation, defense, settlement and discharge of any such claim of intellectual property infringement. You will, however, promptly notify Company in writing of such a claim.
Modifications to Application
Company reserves the right to modify, suspend or discontinue, temporarily or permanently, the Application or any service to which it connects, with or without notice and without liability to you.
Term and Termination
This Agreement shall remain in effect until terminated by You or Company.
Company may, in its sole and absolute discretion, at any time and for any or no reason, suspend or terminate this Agreement and the rights afforded to You hereunder with or without prior notice. Furthermore, if You fail to comply with any terms and conditions of this Agreement, then this Agreement and any rights afforded to You hereunder shall terminate automatically, without any notice or other action by Company. Upon the termination of this Agreement, You shall cease all use of the Application.
Disclaimer of Warranties
Application is provided on an “as is” basis. As such, Company disclaims all warranties about the Application to the fullest extent permitted by law.
YOU ACKNOWLEDGE AND AGREE THAT THE APPLICATION IS PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS, AND THAT YOUR USE OF OR RELIANCE UPON THE APPLICATION AND ANY THIRD PARTY CONTENT AND SERVICES ACCESSED THEREBY IS AT YOUR SOLE RISK AND DISCRETION. COMPANY AND ITS AFFILIATES, PARTNERS, SUPPLIERS AND LICENSORS HEREBY DISCLAIM ANY AND ALL REPRESENTATIONS, WARRANTIES AND GUARANTEES REGARDING THE APPLICATION AND THIRD PARTY CONTENT AND SERVICES, WHETHER EXPRESS, IMPLIED OR STATUTORY, AND INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT. FURTHERMORE, COMPANY AND ITS AFFILIATES, PARTNERS, SUPPLIERS AND LICENSORS MAKE NO WARRANTY THAT (I) THE APPLICATION OR THIRD PARTY CONTENT AND SERVICES WILL MEET YOUR REQUIREMENTS; (II) THE APPLICATION OR THIRD PARTY CONTENT AND SERVICES WILL BE UNINTERRUPTED, ACCURATE, RELIABLE, TIMELY, SECURE OR ERROR-FREE; (III) THE QUALITY OF ANY PRODUCTS, SERVICES, INFORMATION OR OTHER MATERIAL ACCESSED OR OBTAINED BY YOU THROUGH THE APPLICATION WILL BE AS REPRESENTED OR MEET YOUR EXPECTATIONS; OR (IV) ANY ERRORS IN THE APPLICATION OR THIRD PARTY CONTENT AND SERVICES WILL BE CORRECTED.
Limitation of Liability
UNDER NO CIRCUMSTANCES SHALL COMPANY OR ITS AFFILIATES, PARTNERS, SUPPLIERS OR LICENSORS BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR EXEMPLARY DAMAGES ARISING OUT OF OR IN CONNECTION WITH YOUR ACCESS OR USE OF OR INABILITY TO ACCESS OR USE THE APPLICATION AND ANY THIRD PARTY CONTENT AND SERVICES, WHETHER OR NOT THE DAMAGES WERE FORESEEABLE AND WHETHER OR NOT COMPANY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
If any provision of this Agreement is held to be unenforceable or invalid, such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full force and effect.
Amendments to this Agreement
Company reserves the right, at its sole discretion, to modify or replace this Agreement at any time. If a revision is material we will provide at least 30 days' notice prior to any new terms taking effect. What constitutes a material change will be determined at our sole discretion.
If you have any questions about this Agreement, please contact us. PTC Laboratories, Inc. www.ptclabs.com. email@example.com. +1 (573) 442-9948 phone. +1 (573) 442-9870 fax. 300 Portland Street, Suite 300, Columbia, MO 65201.